Eric's questions to Kura Oncology Inc (KURA) leadership • Q4 2024
Question
Eric, on for Salim Syed at Mizuho, asked if recent staffing changes at the FDA have impacted Kura's engagement with the agency or their expectations for review timelines.
Answer
CEO Troy Wilson responded that Kura's direct interactions with the FDA have remained professional, timely, and cooperative, with no indication of disruptions. However, he affirmed that the company will maintain a conservative approach to its public guidance on timelines given the external environment.